跳至主要内容
临床试验/NCT01102101
NCT01102101Unknown3 期

Effect of Opioids in Neuropathic Pain in Postherpetic Patients

Medical University of Vienna4 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2010年8月最近更新:
适应症
相关药物

试验速览

阶段
3 期
入组人数
30
试验地点
4
主要终点
Stimulus-response (SR)-function

研究概览

简要总结

Postherpetic neuralgia (PHN) is often associated with pain and sensory changes and is the leading type of neuropathic pain in modern clinical pain research. It is characterized by a variety of sensory patterns, which may be categorized into "irritable nociceptor" and "impairment of nociceptor". At date, several lines of evidence lead to the assumption, that mechanical hyperalgesia in PHN is based - at least in part - on central nervous processes of sensitization.

In animal studies the investigators have discovered a previously unrecognized effect of opioids, the reversal of long-term potentiation (LTP) at C-fibre synapses, i.e. an opioid-induced depotentiation. In principle, synaptic depotentiation may be permanent or transient. In our study the clinically used ultra-short acting MOR agonist remifentanil normalized synaptic strength after wash-out of the drug. At present it is not known whether opioid-induced depotentiation can be used to the benefit of pain patients.

The aim is to study the hypothesis, that pain in a group of PHN patients with predominant mechanical hyperalgesia is reversed by intravenous remifentanil at a plasma target concentration of 18ng/ml (corresponding to about 0.75 µg/kg/min) for 60 minutes compared with PHN patients of other sensory types.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients suffering from PHN.
  • Pain ≥ 4 out of 10 in numeric rating scale (NRS)
  • Female and male patients above the age of 18
  • Ability to understand/write/read german

排除标准

  • Zoster affecting trigeminal-, opticus region
  • Any somatic pain which is stronger than the neuropathic pain
  • Severe progressive disease
  • Acute cardiac decompensation
  • Known cardiac valve dysfunction
  • Known pulmonary hypertension
  • Cardiac conduction disturbance
  • Active herpetic lesion
  • Opioid therapy
  • Asthma bronchial
  • Chronic obstructive pulmonary disease >GOLD II
  • Severe psychiatric condition
  • Abuse of alcoholic beverages, drug abuse
  • Negative neuropathic symptoms
  • Pregnancy or breast feeding
  • Participation in a clinical trial in the 2 weeks preceding the study
  • Allergy against any medication used in the study protocol

结局指标

主要结局

Stimulus-response (SR)-function

时间窗: 7 days

次要结局

  • Pinprick(7 days)
  • Area of dynamic allodynia(7 days)
  • NRS(7 days)
  • Mechanical pain threshold(7 days)
  • HPPT(7 days)
  • HPTT(7 days)
  • Coolness(7 days)
  • Warmth(7 days)
  • LDPI(7 days)

研究者

申办方类型
Other

研究点 (4)

Loading locations...

相似试验